A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.
about
Epigenetic treatment of solid tumours: a review of clinical trialsHistone deacetylases as targets for treatment of multiple diseasesPhase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosisRole of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid MalignanciesRomidepsin: a novel histone deacetylase inhibitor for cancer.Genomics and epigenomics of colorectal cancer.Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.Targeting of histone deacetylases in brain tumors.Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients.Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat
P2860
Q26773803-F2AEC080-7B16-487B-A2C6-D03C7CF816B6Q27000389-9A7590B2-5325-47BA-9704-CA77BEB37B55Q33393266-C8CC538E-40A3-445D-BB8C-7456EEC88235Q33408000-6C43056E-D554-473B-BFB8-60AB43F19E10Q34363544-3E3FF372-3E2A-4839-B116-9E99C9366B95Q35214924-93376D1B-1F71-445F-B9D0-8F61046CFCFCQ35246513-F9245CAC-F2B4-46D9-A767-910321E7203BQ35939690-45778ADD-9C52-4762-829D-4FA8EA40E0A7Q36084498-41646305-8D78-4723-88A5-99C2C92BE6D1Q37226511-B0B62CE9-4CDA-41CA-8EC5-5DFFB5423994Q37893664-AE4B6DFD-DC1B-47D8-939C-9C54B83E73E0Q38074617-7EA27015-2386-47B9-8721-85049A258CF1Q38118900-E77DBF7C-DD63-457B-B073-F3361B76A7D3Q38233117-FBF0C674-D99D-46D1-AAC5-28ABC321D908Q38726747-F077AE0D-7A5C-476B-9D7B-445924288B34Q39214195-14BCC6AD-E918-471E-8BB9-249E5F1BD45FQ39262034-6672BC2E-EDCF-4DD0-92E4-625AF168501BQ39454860-D7B396FE-8DC2-4CE7-9E22-005DB98457D7Q39485541-973852BD-7FD0-433F-A2BE-EDE32FD29294
P2860
A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A phase I, pharmacokinetic, an ...... with refractory solid tumors.
@ast
A phase I, pharmacokinetic, an ...... with refractory solid tumors.
@en
A phase I, pharmacokinetic, an ...... with refractory solid tumors.
@nl
type
label
A phase I, pharmacokinetic, an ...... with refractory solid tumors.
@ast
A phase I, pharmacokinetic, an ...... with refractory solid tumors.
@en
A phase I, pharmacokinetic, an ...... with refractory solid tumors.
@nl
prefLabel
A phase I, pharmacokinetic, an ...... with refractory solid tumors.
@ast
A phase I, pharmacokinetic, an ...... with refractory solid tumors.
@en
A phase I, pharmacokinetic, an ...... with refractory solid tumors.
@nl
P2093
P2860
P1476
A phase I, pharmacokinetic, an ...... with refractory solid tumors.
@en
P2093
Alan Litwin
Gerald Fetterly
Igor Espinoza-Delgado
James A Zwiebel
Josephia R Muindi
Julianne L Holleran
Kangsheng Wang
Marwan G Fakih
Merrill J Egorin
Robert B Diasio
P2860
P304
P356
10.1158/1078-0432.CCR-10-0547
P407
P577
2010-05-12T00:00:00Z